文献速递临床试验与 GCP基础与转化研究

PROMISE 研究:粪菌移植改善肝硬化患者结局的前瞻性随机双盲安慰剂对照多中心试验方案

PROMISE: a PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve outcomEs in patients with cirrhosis over 24 months-study protocol for a clinical trial.
PubMed 文献 · Trials · 2026-07-31

PROMISE 是一项 3 期多中心、随机、双盲、安慰剂对照试验,计划纳入 300 例酒精相关肝病、代谢功能障碍相关脂肪性肝病及代谢与酒精相关肝病导致的肝硬化患者(MELD-Na 评分 8-16),评估冻干胶囊粪菌移植(FMT)减少感染、失代偿事件和死亡的有效性,主要终点为因感染或失代偿事件至急诊就诊或住院的时间。

要点

  • PROMISE 研究评估冻干胶囊 FMT 在肝硬化患者中的疗效,主要终点为感染或失代偿事件导致的急诊就诊或住院时间。
  • 计划纳入 300 例 ALD、MASLD 或 MetALD 肝硬化患者,MELD-Na 评分 8-16,每 91 天给药一次,持续 21 个月,随访 24 个月。
  • 次要终点包括全因感染、抗生素使用、AMR 发生率、住院率、肝病严重程度评分、生活质量、HADS 评分、酒精使用和死亡率。

核心结论

  • PROMISE 研究将评估冻干胶囊 FMT 在 ALD、MASLD 和 MetALD 肝硬化患者中的疗效和作用机制,FMT 可能通过重建微生物平衡提供非抗生素治疗选择。

研究设计与样本

  • PROMISE 研究是一项 3 期多中心、随机、双盲、安慰剂对照试验,计划纳入 300 例 ALD、MetALD 或 MASLD 肝硬化患者(MELD-Na 评分 8-16)。
  • 参与者按 1:1 随机分配接受 FMT 或匹配安慰剂胶囊,每 91 天一次,持续 21 个月,随访 24 个月。
  • 主要终点为因感染或失代偿事件至急诊就诊或住院的时间。
  • 招募于 2023 年 6 月开始。

关键数值与推荐

  • 纳入标准:ALD、MetALD 或 MASLD 肝硬化,MELD-Na 评分 8-16。
  • 干预:FMT 或匹配安慰剂胶囊每 91 天一次,持续 21 个月,随访 24 个月。
  • 主要终点:因感染或失代偿事件导致急诊就诊或住院的时间。
  • 次要终点包括全肝性失代偿、全因感染、抗生素使用、AMR 发生率、住院率、肝病严重程度评分、生活质量评分、HADS 评分、酒精使用和死亡率。

临床怎么用

  • FMT 可能为 ALD、MASLD 和 MetALD 肝硬化患者提供一种非抗生素治疗选择,通过生态重建微生物平衡来减少感染和失代偿事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cirrhosis have reduced gut bacterial diversity and a gut microbiota dominated by pathobionts. These changes, coupled with increased gut permeability and bacterial translocation, increase susceptibility to infection and death. There is also considerable concern that high antimicrobial exposure in the cirrhotic population drives the development of antimicrobial resistance (AMR). We previously performed a randomised feasibility trial of endoscopically administered jejunal faecal microbiota transplant (FMT) slurry derived from stringently screened donors, and showed it to be safe and well-tolerated in patients with cirrhosis (PROFIT Trial: NCT02862249). FMT was associated with reduced enteropathogenic bacteria in the gut, augmented ammonia excretion, ameliorated systemic inflammation, and enhanced innate immune responses to pathogen challenge. The trial was not powered to detect differences in clinical outcomes. The PROMISE study will evaluate the efficacy of lyophilised encapsulated FMT to reduce infection, decompensating events and mortality in patients with cirrhosis secondary to alcohol-related liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis and metabolic dysfunction and alcohol-related liver disease (MetALD). METHODS: The PROMISE study is a phase 3 multicentre, randomised, double-blinded, placebo-controlled trial that will evaluate encapsulated lyophilised FMT in 300 participants with ALD, MetALD or MASLD cirrhosis (Model for End-Stage Liver Disease Sodium (MELD-Na) score 8-16). Participants will be randomly allocated (1:1) to receive FMT or matched placebo capsules every 91 days for 21 months, with 24-month follow-up. The primary endpoint is time-to-infection or decompensating event resulting in presentation to the emergency department or hospitalisation. Secondary endpoints include all hepatic decompensation, all-cause infection, antibiotic usage, incidence of AMR, hospitalisation rates, liver disease severity scores, quality of life scores, Hospital Anxiety and Depression Scale score (HADS), alcohol use, and mortality. Mechanistic endpoints include quantification of plasma bacterial DNA, plasma and faecal cytokines/biomarkers, plasma and faecal metabolome, faecal proteome, faecal microbiome composition and diversity (including resistome) and monocyte and mucosal-associated invariant T (MAIT) cell frequency, phenotype and function. Recruitment commenced in June 2023. Results will be disseminated via peer-reviewed journals, international conferences and patient support groups. DISCUSSION: The PROMISE study will assess the efficacy and evaluate the mechanisms of action of FMT in patients with ALD, MASLD and MetALD cirrhosis. FMT may provide an alternative non-antibiotic treatment for these patients through ecological reconstitution of microbial balance. TRIAL REGISTRATION: ISRCTN, ISRCTN17863382. Registered on 25th March 2022, https://www.isrctn.com/ISRCTNISRCTN17863382 . CLINICALTRIALS: gov NCT06461208. Registered on 4th June 2024, https://clinicaltrials.gov/study/NCT06461208#study-overview .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kronsten VT, Ntuli Y, Paintsil EK, et al. PROMISE: a PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve outcomEs in patients with cirrhosis over 24 months-study protocol for a clinical trial. Trials. 2026. PMID: 42947250. doi:10.1186/s13063-026-09914-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。